Extended release tablet formulations of venlafaxine
A technology of delayed release and tablet, applied in the field of preparation of the formulation, delayed or slow release tablet formulation, and can solve the problems of difficult preparation, time-consuming preparation, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
example 1
[0040] ingredients
[0041] * Equivalent to 75mg base
[0042] ** Carboxyvinyl polymers are commercially available from BF Goodrich, Pharmaceuticals Division
[0043] Dissolution test
[0044] Dissolution tests were carried out over a 24 hour time course using USP type 2 apparatus in 900 ml water at 100 rpm or in 900 ml simulated medium at 50 rpm. As for the simulated liquid, it was first dissolved in 900ml simulated gastric juice USP (without enzyme) for 2 hours, and then the medium was replaced with 900ml simulated intestinal fluid USP (without enzyme). Dissolution tests were performed at 37°C. 5 ml samples were withdrawn from the dissolution vessel at the required time intervals and the venlafaxine hydrochloride content and thus its dissolution rate were determined by UV spectroscopy. The dissolution data shown are the average of at least 3 tablets.
[0045] result
[0046] The results obtained from the dissolution tests are shown in Table 1 below.
[0047...
example 2
[0065] * Equivalent to 75mg base
[0066] Dissolution test / results
[0067] Dissolution tests were carried out as described in Example 1 and the results shown in Table 4 were obtained:
[0068] time
example 3
[0071] * Equivalent to 75mg base
[0072] Dissolution test / results
[0073] Dissolution tests were carried out as described in Example 1 and the results shown in Table 5 were obtained:
[0074] time
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More